[1] Van Aller GS, Reynoird N, Barbash O, et al. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation[J]. Epigenetics, 2012, 7: 340-343. [2] Bernard BJ, Nigam N, Burkitt K, et al. SMYD3: a regulator of epigenetic and signaling pathways in cancer[J]. Clin Epigenetics, 2021, 13: 45. [3] Fu W, Liu N, Qiao Q, et al. Structural basis for substrate preference of SMYD3, a SET domain-containing protein lysine methyltransferase[J]. J Bio Chem, 2016, 291: 9173-9180. [4] Mazur PK, Reynoird N, Khatri P, et al. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer[J]. Nature, 2014, 510: 283-287. [5] Zhang H, Zheng Z, Zhang R, et al. SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters[J]. Cell Death Dis, 2021, 12: 731. [6] Fenizia C, Bottino C, Corbetta S, et al. SMYD3 promotes the epithelial-mesenchymal transition in breast cancer[J]. Nucleic Acids Res, 2019, 47: 1278-1293. [7] Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data[J]. Nat Commun, 2013, 4: 2612. [8] Li T, Fan J, Wang B, et al. TIMER: a Web server for comprehensive analysis of tumor-infiltrating immune cells[J]. Cancer Res, 2017, 77: e108-e110. [9] Liu D, Schilling B, Liu D, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 block-ade in patients with metastatic melanoma[J]. Nat Med, 2019, 25: 1916-1927. [10] Yamamoto K, Venida A, Yano J, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I[J]. Nature, 2020, 581: 100-105. [11] Dhatchinamoorthy K, Colbert J D, Rock K L. Cancer immune evasion through loss of MHC class Ⅰ antigen presentation[J]. Front Immunol, 2021, 12: 636568. [12] Sarris ME, Moulos P, Haroniti A, et al. Smyd3 is a transcriptional potentiator of multiple cancer-promoting genes and required for liver and colon cancer development[J]. Cancer Cell, 2016, 29: 354-366. |